Dr. Claudia Frehe has over a decade of life sciences patent prosecution experience, with particular depth in antibody therapeutics, gene-editing technologies (including CRISPR and RNA-editing platforms), RNA-based therapeutics, and cell and gene therapy. She draws on her scientific background in clinical immunology, immuno-oncology, and solid organ and stem cell transplantation to craft IP strategies that not only secure strong exclusivity but also support critical business milestones such as raising capital, preparing for an acquisition or IPO, or launching commercially.

By aligning patent strategy with business objectives, Claudia helps translate complex science into scalable, investor-facing assets that provide long-term value. As a patent attorney and previously as a patent agent, she has developed and managed worldwide patent portfolios, drafted and prosecuted patent applications across the life sciences, and is experienced in validity/invalidity, noninfringement, and freedom-to-operate analyses, due diligence, and coordinating worldwide prosecution with foreign associates.

Claudia received her Ph.D. from Baylor College of Medicine, where her research focused on developing and testing novel chimeric antigen receptor T cells targeting solid tumors. She subsequently completed a postdoctoral fellowship in at the National Cancer Institute within the Experimental Transplantation and Immunology Branch. Claudia also brings direct clinical experience to her practice, having earned certification as a clinical molecular biologist (ASCP) and worked at Houston Methodist Hospital, where she conducted pre- and post-operative HLA testing in support of solid organ and stem cell transplantation.